Table S2 from Tumor-Specific MHC-II Activates CD4⁺ and CD8⁺ T Cells in Head and Neck Squamous Cell Carcinoma to Boost Immunotherapy Efficacy

Yuying Zhang; Jinbang Li; Xiaoyu Guo; Zhao Gao; Ji‐An Pan; Sheng Nong; Jin-Lin Ma; Gang Chen; Jiali Zhang

doi:10.1158/0008-5472.30029698

September 2, 2025Open Access

Table S2 from Tumor-Specific MHC-II Activates CD4⁺ and CD8⁺ T Cells in Head and Neck Squamous Cell Carcinoma to Boost Immunotherapy Efficacy

View Full Paper

Ask AI

Bookmark

Share

Key Points

Tumor-specific MHC-II activates CD4+ T cells and CD8+ T cells, enhancing response rates in head and neck cancer.
This activation leads to improved efficacy of immunotherapy, indicating a potential for better treatment strategies.
Potential increase in patient outcomes prompts further exploration of MHC-II’s role in immune responses.
The findings highlight the importance of targeted therapies in maximizing immunotherapeutic effects.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Observational analysis identifies tumor-specific MHC-II as a key factor enhancing CD4+ and CD8+ T cell activation, suggesting a pathway to improve immunotherapy outcomes.

Abstract

Summary of primary antibody information.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/68bb5f076d6d5674bcd02b3c https://doi.org/10.1158/0008-5472.30029698

View Full Paper

Ask AI

Bookmark

Share

Table S2 from Tumor-Specific MHC-II Activates CD4⁺ and CD8⁺ T Cells in Head and Neck Squamous Cell Carcinoma to Boost Immunotherapy Efficacy

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Table S2 from Tumor-Specific MHC-II Activates CD4⁺ and CD8⁺ T Cells in Head and Neck Squamous Cell Carcinoma to Boost Immunotherapy Efficacy

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading